secukinumab

secukinumab is a human monoclonal antibody used for the treatment of several immune-mediated inflammatory diseases. It functions by selectively binding to and neutralizing interleukin-17A, a key cytokine involved in inflammatory processes. Developed by the Swiss pharmaceutical company Novartis, it is marketed under the brand name Cosentyx and is administered via subcutaneous injection. Its approval and use represent a significant advancement in the biologic therapy for conditions like psoriasis, psoriatic arthritis, and ankylosing spondylitis.

Medical uses

Secukinumab is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is also approved for active psoriatic arthritis, often in combination with methotrexate, and for active ankylosing spondylitis in patients who have responded inadequately to conventional therapy. Further approvals include the treatment of non-radiographic axial spondyloarthritis and enthesitis-related arthritis. Clinical trials, such as those published in *The New England Journal of Medicine*, have demonstrated its efficacy in achieving significant skin clearance, as measured by the Psoriasis Area and Severity Index, and in improving joint symptoms and physical function.

Adverse effects

Common adverse reactions include nasopharyngitis, diarrhea, and upper respiratory tract infection. As with many immunosuppressive agents, there is an increased risk of infections, such as candidiasis and, potentially, tuberculosis reactivation. Serious adverse effects may include inflammatory bowel disease exacerbation or new onset, and hypersensitivity reactions including anaphylaxis. Warnings from regulatory bodies like the U.S. Food and Drug Administration and the European Medicines Agency also highlight the potential for exacerbation of pre-existing Crohn's disease. Patients are typically monitored for signs of infection and undergo screening for latent tuberculosis prior to initiation of therapy.

Pharmacology

Secukinumab is a high-affinity fully human immunoglobulin G1/kappa monoclonal antibody that selectively targets and neutralizes interleukin-17A. This cytokine is produced primarily by T helper 17 cells and plays a central role in the pathogenesis of several autoimmune diseases by promoting inflammation and keratinocyte proliferation. By inhibiting the interaction of IL-17A with its receptor, secukinumab blocks the release of pro-inflammatory cytokines and chemokines. Its pharmacokinetics show a half-life of approximately 22 to 31 days, supporting its dosing regimen, which often involves an initial loading period followed by monthly maintenance injections.

History

The development of secukinumab followed the scientific discovery of the IL-23/IL-17 axis as a critical pathway in psoriasis and related conditions. Research conducted at institutions like the University of Zurich and Rockefeller University helped elucidate this pathway. Novartis advanced the molecule through a comprehensive clinical development program, including the pivotal ERASURE and FIXTURE trials for psoriasis. It received its first global approval from the European Medicines Agency in January 2015, followed shortly by clearance from the U.S. Food and Drug Administration later that same month. Subsequent approvals for additional indications were granted following positive results from studies like FUTURE for psoriatic arthritis and MEASURE for ankylosing spondylitis.

Society and culture

Marketed as Cosentyx, secukinumab has become a major product for Novartis, generating significant annual revenue and competing with other biologics such as adalimumab and ustekinumab. Its introduction has influenced treatment guidelines set by organizations like the American Academy of Dermatology and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis. The high cost of biologic therapies, including secukinumab, has been a subject of discussion within healthcare systems, involving entities like the National Institute for Health and Care Excellence in the United Kingdom and insurance providers in the United States. Patient access programs have been established to assist with affordability. Category:Monoclonal antibodies Category:Immunomodulating drugs Category:Novartis